A latest investigation for functional high-risk (FHR) MM, which refer to patients with suboptimal response to induction therapy or early relapse, demonstrated increased mutations in the IL-6/JAK/STAT3 pathway in FHR patients (46). The gene discussed is IL6; the disease is Miyoshi myopathy.